MIF- Thyroxine Interactions in the Pathogenesis of Pulmonary Arterial Hypertension

Inclusion Criteria

• •Subject must be at least 18 years of age and have confirmed pulmonary hypertension (PH) and interstitial lung disease (ILD).
• •ILD was identified on high resolution computed tomography along with a total lung capacity (TLC) \<70% of predicted value on pulmonary function tests (PFTs) with no evidence of pulmonary hypertension on echocardiogram.
• •PAH group patients were defined as patients with a mean pulmonary artery pressure \>25 mmHg at rest and a wedge pressure of \<15 mmHg (millimeters of mercury), measured by right heart catheterization (WHO group I PAH).
• •PH+ILD group, subjects with evidence of ILD on high resolution CT Scan and mean pulmonary artery pressure \>25 mmHg on right heart catheterization.
• •Patient with evidence of Chronic thromboembolic disease on CT angiogram and mean pulmonary artery pressure \>25mmHg on right heart catheterization. (WHO group IV)
• •Patient with Pulmonary Hypertension due to other conditions, such as Sarcoidosis, Gauchers disease, Hemolytic Anemia and Myeloproliferative disorders.
• •Normal control group: Subjects without cardiopulmonary disease, with a normal PFT and ECG.